Previous Page  18 / 25 Next Page
Information
Show Menu
Previous Page 18 / 25 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 58

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

Esophageal Varices:

Esophageal varices are dilated submucosal

distal esophageal veins connecting the portal and systemic

circulations. This happens due to portal hypertension (most

commonly a result of cirrhosis), resistance to portal blood flow,

and increased portal venous blood inflow. The most common

fatal complication of cirrhosis is variceal rupture; the severity of

liver disease correlates with the presence of varices and risk of

bleeding.

Bleeding esophageal varices:

No single treatment for bleeding

esophageal varices is appropriate for all patients and situations.

An algorithm for management of the patient with acute bleeding

is presented in this article. The options for long-term, definitive

therapy and the criteria for selection of each are discussed.

Pathophysiology and management of esophageal varices:

Esophageal varices are one of the most common and severe

complications of chronic liver disease. New aspects in

epidemiology,pathogenesis,andtreatmentofvaricesarereviewed.

Sclerotherapy is the first-line treatment for acute hemorrhage.

Prevention of first or recurrent bleeding is still unsatisfactory.

β-Blockers are slightly superior to sclerotherapy with regard to

prophylaxis of first bleeding. β-Blockers or sclerotherapy may be

used for prophylaxis of recurrent bleeding. However, prophylactic

treatment regimens do not have a major impact on survival.

Combination treatment, new drugs, or new devices may help to

improve the efficacy of prophylactic measures.

Endoscopic Therapy for Esophageal Varices:

Among therapeutic

endoscopic options for esophageal varices (EV), endoscopic

variceal ligation (EVL) has proven more effectiveness and

safety compared with endoscopic sclerotherapy and is currently

considered as the first choice. In acute EV bleeding, vasoactive

therapy(eitherwithterlipressinorsomatostatin)priortoendoscopy

improves outcomes; moreover, antibiotic prophylaxis has to

be generally adopted. Variceal glue injection (cyanoacrylates)

seems to be effective in the treatment of esophageal as well as in

gastric varices. Prevention of rebleeding can be provided both by

EVL alone or combined with non-selective β-blockers. Moreover,

EVL can be adopted for primary prophylaxis, with no differences

in mortality compared with drugs, in subjects with large varices

and unfit for a β-blocker regimen.

A meta‐analysis of endoscopic variceal ligation for primary

prophylaxis of esophageal variceal bleeding:

Despite publication

of several randomized trials of prophylactic variceal ligation, the

effect on bleeding‐related outcomes is unclear. We performed a

meta‐analysis of the trials, as identified by electronic database

searchingandcross‐referencing.Bothinvestigatorsindependently

applied inclusion and exclusion criteria, and abstracted data

from each trial. Standard meta‐analytic techniques were used

to compute relative risks and the number needed to treat (NNT)

for first variceal bleed, bleed‐related mortality, and all‐cause

mortality. Among601patients in5homogeneous trials comparing

prophylactic ligation with untreated controls, relative risks of first

variceal bleed, bleed‐related mortality, and all‐cause mortality

were 0.36 (0.26‐0.50), 0.20 (0.11‐0.39), and 0.55 (0.43‐0.71), with

respective NNTs of 4.1, 6.7, and 5.3. Among 283 subjects from

4 trials comparing ligation with β‐blocker therapy, the relative

risk of first variceal bleed was 0.48 (0.24‐0.96), with NNT of 13;

however, there was no effect on either bleed‐related mortality

(relative risk [RR], 0.61; confidence interval [CI], 0.20‐1.88) or all‐

cause mortality (RR, 0.95; CI, 0.56‐1.62). In conclusion, compared

with untreated controls, prophylactic ligation reduces the risks

of variceal bleeding and mortality. Compared with β‐blockers,

ligation reduces the risk for first variceal bleed but has no effect

on mortality. Prophylactic ligation should be considered for

patients with large esophageal varices who cannot tolerate β‐

blockers. Subsequent research should further compare ligation

and β‐blockers to determine the effect on mortality, and measure

ligation’s cost‐effectiveness.

dr.bsgill1@gmail.com

Pathophysiology and management of esophageal varices in

current practice

Balwant Singh Gill

Swami Ji Gastroenterology Center, Punjab, India

J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-006